This is true, but it is far too technical for a general audience. Even if you consider there is no difference seen in survival between doxorubicin and bisantrene, the side effect profile massively favours bisantrene - 25% of the doxorubicin arm patients ended up in heart failure!
I would add that they upped the dose of bisantrene after the first 45 patients from 260mg/m2 to 320mg/m2. Even after doing this the myleosupression rate was lower in the bisantrene arm suggesting the bisantrene patients were still being under dosed.
This is true, but it is far too technical for a general...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |